ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe
Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, recently announced that the European Commission has granted Marketing Authorisation for Tivicay (dolutegravir) 5mg dispersible tablets, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least four weeks and weighing at least 3kg. This authorisation includes updated dosing recommendations, for Tivicay (dolutegravir) film-coated tablets (10mg, 25mg and 50mg) for children 6 years and older and weighing at least 14kg, bringing these in line with the World Health Organization weight bands.

Deborah Waterhouse, CEO of ViiV Healthcare, said: “Today’s authorisation is a really important milestone towards enabling children to have access to age-appropriate formulations of HIV medicine. Globally there are approximately 1.7 million children living with HIV and around 100,000 children dying each year from AIDS which is why we won’t stop doing all that we can to ensure that no child living with HIV is left behind.”

The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020[1], providing an age-appropriate formulation of dolutegravir for a younger population to help to close the gap between HIV treatment options available for adults and children.

Amanda Ely, CEO of CHIVA (Children’s HIV Association) said: “As an organisation, we continue our efforts to help support young people and families living with HIV manage the challenges of lifelong treatment and today’s authorisation helps to do this. Today’s news is a positive step forward in helping the many children and infants who may struggle to take their medicines in tablet form.”

The Marketing Authorisation is based on data from the ongoing P1093[2] and ODYSSEY[3] (PENTA20) studies, which are being conducted in collaboration with international paediatric research networks, IMPAACT and PENTA-ID.

Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors inhibit HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.

Tags : #ViiVHealthcare #LatestNewsonViiVHealthcare15thJan #LatestPharmaNews15thJan #GlaxoSmithKline #PfizerInc #ShionogiLtd #ChildrenWithHIV #TreatmentforHIV #USFDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Hypertension in India: A Silent EpidemicMay 16, 2025
Know Your Blood Pressure & Keep It Under CheckMay 16, 2025
SBI Securities Contributed ₹49 Lakh to Enhance Eye Care Services in Odisha and West Bengal.May 16, 2025
7 Must Have Apps to Help You Break Free and Redefine Your Daily RoutineMay 16, 2025
Çelebi Aviation India Refutes False Allegations; Reaffirms Its Long-standing Commitment to India’s Aviation SectorMay 16, 2025
The Belly Bulge That Predicts the Future: What Every Parent Must KnowMay 16, 2025
Your Brain is Shrinking And Your Chair Might Be to BlameMay 16, 2025
Dengue on the Rise in India: A Wake-Up CallMay 15, 2025
Mumbai to Host Inter Passenger Terminal Show 2025 (IPTS 2025) May 15, 2025
Sharda Care Healthcity Saves 4-Year-Old Girl from Limb Amputation After Severe, Neglected InjuryMay 15, 2025
Indian students at Universities of Birmingham and Glasgow to get competitive advantage through exclusive careers supportMay 15, 2025
SIMS Hospital Performs South India’s First Combined Beating Heart Four Vessel Bypass and Pacemaker Implantation on 92-Year-Old DoctorMay 15, 2025
CoinDCX eyes over 30% of its revenue from the MENA region May 15, 2025
SBI Card Partners Apollo HealthCo; Introduces Apollo SBI Card SELECT CardMay 15, 2025
Top 5 E-Commerce Platforms in India for Your Every NeedMay 15, 2025
A for Accountability and Audit for TB deaths is missing in #EndTB responseMay 15, 2025
Inside India Inc’s Emotional Struggle: 84% of Employees Report Low Mood, Says HCL HealthcareMay 15, 2025
Early Signs of Alzheimer’s: What Doctors MissMay 15, 2025
Case based approach to Chronic Back Pain:May 15, 2025
Sensodyne’s latest campaign, addresses tooth sensitivity through real voicesMay 14, 2025